Arcadia Biosciences, Inc.
RKDA
$3.46
$0.20196.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.31M | 4.88M | 4.64M | 4.63M | 4.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.31M | 4.88M | 4.64M | 4.63M | 4.60M |
| Cost of Revenue | 3.43M | 2.75M | 2.53M | 2.56M | 2.52M |
| Gross Profit | 1.88M | 2.12M | 2.11M | 2.06M | 2.09M |
| SG&A Expenses | 10.76M | 9.81M | 9.43M | 8.82M | 9.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.25M | 12.62M | 12.02M | 11.44M | 12.28M |
| Operating Income | -8.93M | -7.75M | -7.38M | -6.82M | -7.68M |
| Income Before Tax | -5.78M | -2.20M | -1.66M | -351.00K | -7.13M |
| Income Tax Expenses | 8.00K | 7.00K | 7.00K | 8.00K | 8.00K |
| Earnings from Continuing Operations | -5.79 | -2.21 | -1.66 | -0.36 | -7.14 |
| Earnings from Discontinued Operations | -1.25M | -3.62M | -5.12M | -6.67M | -6.85M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 0.00 | 5.00K | 5.00K |
| Net Income | -7.04M | -5.83M | -6.78M | -7.02M | -13.98M |
| EBIT | -8.93M | -7.75M | -7.38M | -6.82M | -7.68M |
| EBITDA | -8.82M | -7.59M | -7.15M | -6.55M | -7.39M |
| EPS Basic | -5.16 | -4.28 | -4.98 | -5.16 | -14.23 |
| Normalized Basic EPS | -4.40 | -2.71 | -2.46 | -0.02 | -5.59 |
| EPS Diluted | -5.16 | -4.28 | -4.98 | -5.16 | -14.24 |
| Normalized Diluted EPS | -4.40 | -2.71 | -2.46 | -0.02 | -5.59 |
| Average Basic Shares Outstanding | 5.45M | 5.45M | 5.45M | 5.44M | 4.94M |
| Average Diluted Shares Outstanding | 5.45M | 5.45M | 5.45M | 5.44M | 4.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |